Arcuate Therapeutics
Boston, US · Founded 2019 · Delaware corporation
Find your way into Arcuate Therapeutics
Sign up to see every warm intro you have to Arcuate Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arcuate Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
AL
Andrew LevinNamed on SEC filing
JR
Joshua ResnickNamed on SEC filing
AB
Aaron BergenerNamed on SEC filing
JS
James SchneiderNamed on SEC filing
SR
Sarah ReedNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2019
▶$5MraisedOct 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$5MraisedOct 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinExecutive Officer, Director
- Joshua ResnickDirector
- Aaron BergenerExecutive Officer
- James SchneiderExecutive Officer
- Sarah ReedExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Arcuate Therapeutics raised?
- Arcuate Therapeutics has disclosed $5M raised across 1 round.
- Where is Arcuate Therapeutics headquartered?
- Arcuate Therapeutics is headquartered in Boston, US.